Bushentongluo formula counteracts BMSCs senescence to alleviate postmenopausal osteoporosis by activating mitophagy via the SENP1-SIRT3 pathway.

Shuai Chen, Lingling Yu, Ningsheng Tian, Qilong Zhao, Miaochao Qin, Liansheng Shao, Pengfei Sun, Peng Ma, Junwu Wang, Penghua Fang, Wen Min

Department of Orthopaedics, Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Provincial Hospital of Traditional Chinese Medicine, Nanjing 210029, China; Key Laboratory for Metabolic Diseases in Chinese Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, China.Department of Orthopaedics, Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Provincial Hospital of Traditional Chinese Medicine, Nanjing 210029, China; Key Laboratory for Metabolic Diseases in Chinese Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, China. · pubmed

Paper

Abstract

Senescence and impaired osteogenic capacity of bone marrow mesenchymal stem cells (BMSCs) are pivotal pathogenic drivers in the progression of postmenopausal osteoporosis (PMOP). The Bushentongluo formula (BSTLF) is a traditional Chinese herbal prescription that has shown beneficial clinical outcomes in the treatment of PMOP, yet its underlying mechanisms remain unclear.

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

The paper claims that the Bushentongluo formula counteracts BMSCs senescence to alleviate postmenopausal osteoporosis by activating mitophagy via the SENP1-SIRT3 pathway. This research addresses the senescence of stem cells, which is a fundamental aspect of aging and its associated diseases, making it relevant to longevity research.

Author of this paper? Send a correction.